This webinar takes place on Thursday November 21st between 15.00 and 15.30 CET / 14.00-14.30 GMT / 9.00-9.30 AM EST.
Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.
THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.
Abstract:
Insoluble aggregates (Lewy bodies) consisting of misfolded alpha-synuclein accumulate in the nervous system of most Parkinson’s disease patients. This process can affect multiple cellular functions, eventually leading to neuronal death. From a drug discovery perspective, preventing protein aggregation or promoting protein clearance provide interesting opportunities as pharmacological intervention points.
In this webinar, we will present a high-capacity in vitro model of alpha-synuclein aggregation and how it was used to identify targets involved in the modulation of alpha-synuclein aggregation. Using lentiviral knock-down combined with high content imaging and analysis as well as gene expression analysis, targets were identified and validated. In addition to RNA knock-down approaches, the presented in vitro model could be used to evaluate how different modalities modulate alpha-synuclein aggregation and cell health and, together with orthogonal assays, be a useful tool in lead identification and lead optimization activities.